Marina Y Konopleva

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc The bone marrow microenvironment as niche retreats for hematopoietic and leukemic stem cells
    Felix Nwajei
    Department of Immunology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0902, Houston, TX 77030, USA Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, 6767 Bertner Avenue, 3rd Floor, Houston, TX 77030, USA
    Adv Hematol 2013:953982. 2013
  2. pmc Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104
    Juliana Benito
    Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e23108. 2011
  3. ncbi request reprint Targeting the leukemia microenvironment
    Marina Konopleva
    Section of Molecular Hematology and Therapy and Department of Stem Cell Transplantation and Cellular Therapies, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Curr Drug Targets 8:685-701. 2007
  4. doi request reprint Leukemia stem cells and microenvironment: biology and therapeutic targeting
    Marina Y Konopleva
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    J Clin Oncol 29:591-9. 2011
  5. pmc Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches
    Marina Konopleva
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Drug Resist Updat 12:103-13. 2009
  6. pmc Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia
    Farhad Ravandi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    J Clin Oncol 28:1856-62. 2010
  7. pmc Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase
    Jorge E Cortes
    Departments of Leukemia and Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:392-7. 2010
  8. ncbi request reprint Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen
    Mary Ann Weiser
    Department of General Internal Medicine, Ambulatory Treatment and Emergency Care, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:1179-85. 2004
  9. pmc Apoptosis in leukemias: regulation and therapeutic targeting
    Ismael Samudio
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer Treat Res 145:197-217. 2010
  10. pmc Antidiabetic therapies affect risk of pancreatic cancer
    Donghui Li
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Gastroenterology 137:482-8. 2009

Detail Information

Publications56

  1. pmc The bone marrow microenvironment as niche retreats for hematopoietic and leukemic stem cells
    Felix Nwajei
    Department of Immunology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0902, Houston, TX 77030, USA Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, 6767 Bertner Avenue, 3rd Floor, Houston, TX 77030, USA
    Adv Hematol 2013:953982. 2013
    ....
  2. pmc Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104
    Juliana Benito
    Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e23108. 2011
    ..Together, these findings strongly suggest that targeting hypoxia in leukemic BM is feasible and may significantly improve leukemia therapy...
  3. ncbi request reprint Targeting the leukemia microenvironment
    Marina Konopleva
    Section of Molecular Hematology and Therapy and Department of Stem Cell Transplantation and Cellular Therapies, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Curr Drug Targets 8:685-701. 2007
    ..Focus on this stroma-leukemia crosstalk may result in the development of strategies that alleviate the acquisition of a chemoresistant phenotype and enhance the efficacy of therapies in hematological malignancies...
  4. doi request reprint Leukemia stem cells and microenvironment: biology and therapeutic targeting
    Marina Y Konopleva
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    J Clin Oncol 29:591-9. 2011
    ..New strategies that exploit potentially unique properties of the LSCs and their microenvironment are discussed...
  5. pmc Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches
    Marina Konopleva
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Drug Resist Updat 12:103-13. 2009
    ..This complex interplay provides a rationale for appropriately tailored molecular therapies targeting not only leukemic cells but also their microenvironment to ensure improved outcomes in leukemia...
  6. pmc Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia
    Farhad Ravandi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    J Clin Oncol 28:1856-62. 2010
    ..Plasma inhibitory assay demonstrated an on-target effect on FLT3 kinase activity. CONCLUSION Sorafenib can be safely combined with chemotherapy, produces a high CR rate in FLT3-mutated patients, and inhibits FLT3 signaling...
  7. pmc Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase
    Jorge E Cortes
    Departments of Leukemia and Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:392-7. 2010
    ..Although most patients with chronic myeloid leukemia (CML) in chronic phase respond well to front-line therapy with imatinib, some patients do not achieve the desirable end point, and others may eventually lose response or are intolerant...
  8. ncbi request reprint Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen
    Mary Ann Weiser
    Department of General Internal Medicine, Ambulatory Treatment and Emergency Care, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:1179-85. 2004
    ....
  9. pmc Apoptosis in leukemias: regulation and therapeutic targeting
    Ismael Samudio
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer Treat Res 145:197-217. 2010
    ..This chapter will review our understanding of the molecular circuitry that controls apoptosis in leukemia and the pharmacological manipulations of this pathway that may yield therapeutic benefit...
  10. pmc Antidiabetic therapies affect risk of pancreatic cancer
    Donghui Li
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Gastroenterology 137:482-8. 2009
    ..We investigated the effect of antidiabetic therapies on the risk of pancreatic cancer...
  11. pmc Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia
    Steven M Kornblau
    Section of Molecular Hematology and Therapy, Unit 448, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 108:2358-65. 2006
    ..It is thus likely that only combinations of agents that target the multiply activated STPs will be beneficial for patients with AML...
  12. pmc MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy
    Kensuke Kojima
    Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 448, Houston, TX 77030, USA
    Blood 106:3150-9. 2005
    ..p53 activation by targeting the p53-MDM2 interaction might offer a novel therapeutic strategy for AML that retain wild-type p53...
  13. ncbi request reprint 2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancer
    Ismael Samudio
    Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Biol Chem 280:36273-82. 2005
    ..These results suggest that CDDO and its derivatives may offer a clinical benefit for the treatment of PC...
  14. ncbi request reprint Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
    Marina Konopleva
    Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Cell 10:375-88. 2006
    ..These data suggest that ABT-737 could be a highly effective antileukemia agent when the mechanisms of resistance identified here are considered...
  15. doi request reprint Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax)
    Marina Konopleva
    Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 68:3413-20. 2008
    ..In conclusion, we show that obatoclax potently induces apoptosis and decreases leukemia cell proliferation and may be used in a novel therapeutic strategy for AML alone and in combination with other targeted agents and chemotherapeutics...
  16. ncbi request reprint Drug-resistant breast carcinoma (MCF-7) cells are paradoxically sensitive to apoptosis
    Jack S K Chen
    Department of Bioimmunotherapy, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Cell Physiol 200:223-34. 2004
    ....
  17. ncbi request reprint The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells
    Marina Konopleva
    Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Br J Haematol 118:521-34. 2002
    ..These findings could be used in the development of therapies that selectively induce apoptosis in quiescent leukaemic progenitor cells...
  18. ncbi request reprint Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK
    Alina Felicia Nica
    Institute of Molecular Medicine, University of Texas Health Science Center, Houston, Texas, USA
    Cell Cycle 7:3362-70. 2008
    ..The findings presented here suggest that Caspase-8, JNK, and perhaps MCL-1 may play important roles in regulating cell death and may represent new targets for therapeutic strategies for CML...
  19. ncbi request reprint The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia
    Marina Konopleva
    Section of Molecular Hematology and Therapy and the Department of Blood and Marrow Transplantation at The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer Res 64:7927-35. 2004
    ..The direct modulation of mitochondrial-mediated, caspase-independent apoptosis by CDDO may be advantageous for overcoming chemoresistance in AML...
  20. ncbi request reprint Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia
    Marina Konopleva
    Department of Blood and Marrow Transplantation, Section of Molecular Hematology and Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 99:326-35. 2002
    ..Differential effects of CDDO-Me on leukemic and normal progenitor cells suggest that CDDO-Me has potential as a novel compound in the treatment of hematologic malignancies...
  21. ncbi request reprint Mechanisms of drug resistance in AML
    Michael Andreeff
    Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer Treat Res 112:237-62. 2002
  22. ncbi request reprint Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells
    Yoko Tabe
    Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 67:684-94. 2007
    ....
  23. ncbi request reprint Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias
    Marina Konopleva
    Section of Molecular Hematology and Therapy and Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Ther 3:1249-62. 2004
    ....
  24. pmc Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells
    Ismael Samudio
    Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Ther 7:1130-9. 2008
    ..CDDO-Me is in clinical trials and shows signs of clinical activity, with minimal side effects and complete lack of cardiotoxicity. Studies in leukemias are in preparation...
  25. pmc Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
    Zhihong Zeng
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 113:6215-24. 2009
    ..Disruption of these interactions with CXCR4 inhibitors represents a novel strategy of sensitizing leukemic cells by targeting their protective bone marrow microenvironment...
  26. pmc Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction
    Ismael Samudio
    Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    J Clin Invest 120:142-56. 2010
    ..The results support the concept of FAO inhibitors as a therapeutic strategy in hematological malignancies...
  27. ncbi request reprint PML-RARalpha is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival
    Yoko Tabe
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 103:1815-22. 2004
    ..This report provides a mechanistic basis for the BM adipocyte-leukemia cell interaction and suggests that OB-R receptor blockade may have therapeutic use in APL...
  28. ncbi request reprint Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia
    Michele Milella
    Department of Blood and Marrow Transplantation, Section of Molecular Hematology and Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 99:3461-4. 2002
    ..These findings show that the Bcl-2 and MAPK pathways are relevant molecular targets in AML and that their concurrent inhibition could be developed into a new therapeutic strategy for this disease...
  29. ncbi request reprint Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML
    Kensuke Kojima
    Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cell Cycle 5:2778-86. 2006
    ..Our data suggest that combined targeting of Mdm2 and Bcl-2 proteins could offer considerable therapeutic promise in AML...
  30. ncbi request reprint Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells
    Marina Konopleva
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 65:9962-70. 2005
    ..This DeltaRaf:ER system can serve as a preclinical model to evaluate the effects of signal transduction inhibitors which target the Raf and MEK proteins...
  31. ncbi request reprint PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter
    Yoko Tabe
    Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1400 Holcombe Boulevard, Unit 448, Houston, TX 77030, USA
    Ann Hematol 85:689-704. 2006
    ..These results demonstrate that oncogenic PML-RARalpha and AML1-ETO translocations are rarely associated with RARbeta2 promoter methylation in primary AML samples...
  32. ncbi request reprint Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance
    Bing Z Carter
    The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cell Cycle 5:2223-9. 2006
    ..Therefore, Eg5 could be a potential therapeutic target for the treatment of BC CML, in particular Imatinib-resistant BC CML...
  33. ncbi request reprint A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells
    Shishir Shishodia
    Cytokine Research Laboratory, Department of Experimental Therapeutics, Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 12:1828-38. 2006
    ....
  34. ncbi request reprint PPARgamma-active triterpenoid CDDO enhances ATRA-induced differentiation in APL
    Yoko Tabe
    Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer Biol Ther 6:1967-77. 2007
    ..In summary, these results provide rationale for the combined targeting of RAR and PPARgamma nuclear receptors in the therapy of APL...
  35. pmc Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells
    Yoko Tabe
    Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, Unit 448, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Blood 107:1546-54. 2006
    ....
  36. pmc Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim
    Weiguo Zhang
    Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer Res 70:2424-34. 2010
    ..These results strongly indicate the therapeutic potential of combined MEK/MDM2 blockade in AML and implicate Puma and Bim as major regulators of AML cell survival...
  37. ncbi request reprint Guggulsterones induce apoptosis and differentiation in acute myeloid leukemia: identification of isomer-specific antileukemic activities of the pregnadienedione structure
    Ismael Samudio
    Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Unit 448, 1400 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 4:1982-92. 2005
    ....
  38. pmc Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia
    Kensuke Kojima
    Department of Blood and Marrow Transplantation, Section of Molecular Hematology and Therapy, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, 77030, USA
    Blood 108:993-1000. 2006
    ..Results suggest that the nongenotoxic activation of p53 by targeting the Mdm2-p53 interaction provides a novel therapeutic strategy for CLL...
  39. pmc Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells
    Duncan H Mak
    Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Ther 8:2509-16. 2009
    ....
  40. pmc Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemia
    Twee Tsao
    Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer Res 70:4949-60. 2010
    ....
  41. ncbi request reprint Growth-inhibitory effect of a novel synthetic triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, on ovarian carcinoma cell lines not dependent on peroxisome proliferator-activated receptor-gamma expression
    Bohuslav Melichar
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 93:149-54. 2004
    ..CDDO is a ligand for the peroxisome proliferator-activated receptor-gamma (PPARgamma). The aim of the present study was to evaluate CDDO activity in EOC cell lines in vitro...
  42. ncbi request reprint Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias
    Zhihong Zeng
    Department of Blood and Marrow Transplantation, Section of Molecular Hematology and Therapy, Unit 448, 1515 Holcombe Boulevard, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Ther 5:3113-21. 2006
    ..Disruption of these interactions by the peptide CXCR4 inhibitor RCP168 represents a novel strategy for targeting leukemic cells within the bone marrow microenvironment...
  43. ncbi request reprint Spontaneous migration of acute promyelocytic leukemia cells beneath cultured bone marrow adipocytes with matched expression of the major histocompatibility complex
    Yoko Tabe
    Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Rinsho Byori 52:642-8. 2004
    ..This match in MHC expression may play a role in the intimate cell-to-cell interactions that support the anti-apoptotic effects of the membrane-bound leptin signaling pathway...
  44. pmc Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML
    Zhihong Zeng
    Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 109:3509-12. 2007
    ..Our study provides the first evidence that rapamycin derivatives inhibit AKT signaling in primary AML cells both in vitro and in vivo, and supports the therapeutic potential of mTOR inhibition strategies in leukemias...
  45. ncbi request reprint Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survival
    Giuseppe Monaco
    Department of Human Genetics, Baylor College of Medicine, Houston, Texas, USA
    Stem Cells 22:188-201. 2004
    ..In conclusion, we demonstrated that CXCR4 is not critical for the engraftment of AML CD34+ cells in NOD/SCID mice. The model may, however, reflect the clinical course of the disease...
  46. doi request reprint Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia
    Weiguo Zhang
    Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Natl Cancer Inst 100:184-98. 2008
    ..The kinase inhibitor sorafenib induces growth arrest and apoptosis at much lower concentrations in AML cell lines that harbor FLT3-ITD mutations than in AML cell lines with wild-type FLT3...
  47. ncbi request reprint Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance
    Julianne M Davis
    Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC 27858, USA
    Clin Cancer Res 9:1161-70. 2003
    ..These observations suggest both independent and overlapping roles for Raf-1 and Bcl-2 oncogenes in the resistance to growth inhibition by doxorubicin...
  48. ncbi request reprint Expression of inducible Bcl-X(S) in myeloid leukemia: compensatory upregulation of Bcl-X(L) and Bcl-2 prevents apoptosis and chemosensitization
    Frank Tacke
    Department of Gastroenterology, Hepatology and Endocrinolog, Hannover Medical School, Hannover, Germany
    Cancer Biol Ther 3:340-7. 2004
    ..These results suggest the existence of a regulatory mechanism aimed to protect leukemic cells from pro-apoptotic stimuli...
  49. ncbi request reprint 2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid and related compounds inhibit growth of colon cancer cells through peroxisome proliferator-activated receptor gamma-dependent and -independent pathways
    Sudhakar Chintharlapalli
    Department of Biochemistry and Biophysics, Texas A and M University, College Station, TX 77843 4466, USA
    Mol Pharmacol 68:119-28. 2005
    ....
  50. ncbi request reprint Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors
    Aaron D Schimmer
    Burnham Institute for Medical Research, La Jolla, California 92037, USA
    Cancer Res 66:2367-75. 2006
    ....
  51. pmc Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia
    Kensuke Kojima
    Department of Hematology, Wakayama Medical University, Wakayama, Japan
    Blood 112:2886-95. 2008
    ..Our findings provide the molecular rationale for concomitant targeting of Aurora kinases and Mdm2 in AML where TP53 mutations are rare and downstream p53 signaling is mostly intact...
  52. ncbi request reprint A novel ring-substituted diindolylmethane,1,1-bis[3'-(5-methoxyindolyl)]-1-(p-t-butylphenyl) methane, inhibits extracellular signal-regulated kinase activation and induces apoptosis in acute myelogenous leukemia
    Rooha Contractor
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer Res 65:2890-8. 2005
    ..Together, these findings suggest that diindolylmethanes are a new class of compounds that selectively induce apoptosis in AML cells through the modulation of the extracellular signal-regulated kinase and PPARgamma signaling pathways...
  53. ncbi request reprint MEK blockade converts AML differentiating response to retinoids into extensive apoptosis
    Michele Milella
    Division of Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy
    Blood 109:2121-9. 2007
    ..Taken together, these results indicate that combined retinoid treatment and MEK blockade exert powerful antileukemic effects and could be developed into a novel therapeutic strategy for both AML and APL...
  54. doi request reprint CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells
    Linhua Jin
    Department of Clinical Pathology, Juntendo University School of Medicine, Tokyo, Japan
    Mol Cancer Ther 7:48-58. 2008
    ..Altogether, these findings suggest that the up-regulation of CXCR4 by imatinib promotes migration of CML cells to bone marrow stroma, causing the G0-G1 cell cycle arrest and hence ensuring the survival of quiescent CML progenitor cells...
  55. ncbi request reprint Correlation between CXCR4 and homing or engraftment of acute myelogenous leukemia
    Giuseppe Monaco
    Cancer Res 64:6832 author reply 6832-3. 2004